Minimal dose inhaled salbutamol leading to diastolic hypotension (rare presentation) and significant lactic acidosis mimicking shock, a case report from tertiary care hospital in Ajman, UAE
DOI:
https://doi.org/10.18203/2349-3291.ijcp20250415Keywords:
Asthma exacerbations, Salbutamol adverse drug reaction, Lactic acidosis, Diastolic hypotensionAbstract
Salbutamol is a selective β2-receptor agonist widely used to treat asthma in both emergency and outpatient settings. It has been associated with a various side effects ranging from mild to severe in presentation. Lactic acidosis and diastolic hypotension are rarely reported together following intermittent salbutamol nebulization in children, even less so at standard therapeutic doses. We present the case of an 11-year-old Emirati male child, known asthmatic but not on any preventive therapy, who experienced a serious drug reaction during an asthma exacerbation following inhaled salbutamol (5 mg back to back, overall 5 to 10 mg. while he was receiving the second dose of salbutamol nebulization in our emergency department, he developed persistent hypotension (lowest 70/45) despite fluid boluses, also he had elevated blood lactate levels (peak concentration 9 mmol/l), following the hyperglycemia (peak concentration 18 mmol/l), hypokalemia (lowest concentration 3.3 mEq/l).The aforementioned alterations improved within 24 hours after discontinuation of salbutamol and without any further fluid boluses which has been initiated initially at the causality based on the presentation that was mimicking shock status. We reinforce the message that even the use of intermittent nebulized salbutamol for acute moderate asthma can lead to severe transient complications in children. Then, healthcare providers should pay attention not only in emergency settings, to achieve prompt recognition and proper management of this adverse reaction. Careful reassessment could prevent similar reactions and further serious complications.
Metrics
References
Gazarian M, Henry RL, Wales SR, Micallef BE, Rood EM, O’Meara MW, et al. Evaluating the efectiveness of evidence-based guidelines for the use of spacer devices in children with acute asthma. Med J Aust. 2001;174:394–7. DOI: https://doi.org/10.5694/j.1326-5377.2001.tb143340.x
Sears MR. Adverse effects of beta-agonists. J Allergy Clin Immunol. 2002;10(6):322-8. DOI: https://doi.org/10.1067/mai.2002.129966
Leung JS, Johnson DW, Sperou AJ, Crotts J, Saude E, Hartling L, et al. A systematic review of adverse drug events associated with administration of common asthma medications in children. PLoS ONE. 2017;12(8):182738. DOI: https://doi.org/10.1371/journal.pone.0182738
Johnson M. The beta-adrenoceptor. Am J Respir Crit Care Med. 1998;158:146-56. DOI: https://doi.org/10.1164/ajrccm.158.supplement_2.13tac110
Phillips PJ, Vedig AE, Jones PL. Metabolic and cardiovascular side efects of the beta 2-adrenoceptor agonists salbutamol and rimiterol. Br J Clin Pharmacol. 1980;9:483–91. DOI: https://doi.org/10.1111/j.1365-2125.1980.tb05844.x
D’Auria E, Mandelli M, Di Dio F, Riva E. Urine retention in a child treated with oral salbutamol. Indian J Pharmacol. 2012;44(4):518–9. DOI: https://doi.org/10.4103/0253-7613.99338
Sarnaik SM, Saladino RA, Manole M. Diastolic hypotension is an unrecognized risk factor for β-agonist-associated myocardial injury in children with asthma. Pediatr Crit Care Med. 2013;14(6):273–9. DOI: https://doi.org/10.1097/PCC.0b013e31828a7677
Carroll CL, Coro M, Cowl A. Transient occult cardiotoxicity in children receiving continuous beta-agonist therapy. World J Pediatr. 2014;10:324-9. DOI: https://doi.org/10.1007/s12519-014-0467-z
Wisecup S, Eades S, Hashmi SS. Diastolic hypotension in pediatric patients with asthma receiving continuous albuterol. J Asthma. 2015;52(7):693–8. DOI: https://doi.org/10.3109/02770903.2014.1002566
Fagbuyi DB, Venkataraman S, Carter JR. Diastolic hypotension, troponin elevation, and electrocardiographic changes associated with the management of moderate to severe asthma in children. Acad Emerg Med. 2016;23:816–22. DOI: https://doi.org/10.1111/acem.12997
Smith ZR, Horng M, Rech MA. Medication-induced hyperlactatemia and lactic acidosis: a systematic review of the literature. Pharmacotherapy. 2019;39(9):946–63. DOI: https://doi.org/10.1002/phar.2316
Dawson KP, Penna AC, Manglick P. Acute asthma, salbutamol and hyperglycaemia. Acta Paediatr. 1995;84(3):305–7. DOI: https://doi.org/10.1111/j.1651-2227.1995.tb13633.x
Shurman A, Passero MA. Unusual vascular reactions to albuterol. Arch Intern Med. 1984;144:1771–2. DOI: https://doi.org/10.1001/archinte.144.9.1771
Habashy D, Lam TL, Browne GJ. The administration of β2-agonists for paediatric asthma and its adverse reaction in Australian and New Zealand emergency departments: a cross-sectional survey. Eur J Emerg Med. 2003;10:219–24. DOI: https://doi.org/10.1097/00063110-200309000-00012
Liamis G, Milionis HJ, Elisaf M. Pharmacologically-induced metabolic acidosis: a review. Drug Saf. 2010;33(5):371–91. DOI: https://doi.org/10.2165/11533790-000000000-00000
Saadia AT, George M, Haesoon L. Lactic acidosis and diastolic hypotension after intermittent albuterol nebulization in a pediatric patient. Resp Med Case Rep. 2015;16:89–91. DOI: https://doi.org/10.1016/j.rmcr.2015.08.005
Meert KL, McCaulley L, Sarnaik AP. Mechanism of lactic acidosis in children with acute severe asthma. Pediatr Crit Care Med. 2012;13(1):28–31. DOI: https://doi.org/10.1097/PCC.0b013e3182196aa2
Naranjo CA, Busto U, Sellers EM. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45. DOI: https://doi.org/10.1038/clpt.1981.154
Liedtke AG, Lava SAG, Milani GP. Selective β2-adrenoceptor agonists and relevant hyperlactatemia: systematic review and meta-analysis. J Clin Med. 2019;9(1):71. DOI: https://doi.org/10.3390/jcm9010071
Seay BM, Prabhakaran S, Abu-Hasan M. Lactic acidosis in status asthmati - cus: a potential side efect of albuterol treatment. Am J Respir Crit Care Med. 2016;193:5615.
Downloads
Published
How to Cite
Issue
Section
